SEHK:3613Pharmaceuticals
Beijing Tong Ren Tang Chinese Medicine (SEHK:3613) Margin Compression Challenges Bullish Quality Narrative
How Beijing Tong Ren Tang Chinese Medicine's FY 2025 Numbers Set Up the Next Chapter
Beijing Tong Ren Tang Chinese Medicine (SEHK:3613) has just posted FY 2025 first half numbers, with revenue of HK$761.7 million and basic EPS of HK$0.28, setting the tone for how investors will read the rest of the year. Over the last three reported halves, revenue has moved from HK$664.5 million in 1H 2024 to HK$947.1 million in 2H 2024 and now HK$761.7 million in 1H 2025, while basic EPS has tracked...